Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-17-164184
Filing Date
2017-05-09
Accepted
2017-05-09 16:11:04
Documents
57
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d366671d10q.htm 10-Q 496713
2 EX-31.1 d366671dex311.htm EX-31.1 7052
3 EX-31.2 d366671dex312.htm EX-31.2 7066
4 EX-32.1 d366671dex321.htm EX-32.1 3352
5 EX-32.2 d366671dex322.htm EX-32.2 3400
  Complete submission text file 0001193125-17-164184.txt   3973271

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT casc-20170331.xml EX-101.INS 896881
7 XBRL TAXONOMY EXTENSION SCHEMA casc-20170331.xsd EX-101.SCH 48733
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE casc-20170331_cal.xml EX-101.CAL 27069
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE casc-20170331_def.xml EX-101.DEF 318679
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE casc-20170331_lab.xml EX-101.LAB 264575
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casc-20170331_pre.xml EX-101.PRE 333146
Mailing Address 2601 FOURTH AVENUE SUITE 500 SEATTLE WA 98121
Business Address 2601 FOURTH AVENUE SUITE 500 SEATTLE WA 98121 (206) 801-2100
Cascadian Therapeutics, Inc. (Filer) CIK: 0001412067 (see all company filings)

EIN.: 260868560 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33882 | Film No.: 17826516
SIC: 8731 Services-Commercial Physical & Biological Research